Cost-effectiveness analyses and utility weights
Published cost-effectiveness analyses and health-state utility weights that a model of this product could cite, adapt, or compare against, grouped by how each article relates to the product and its indication. Every value is quoted from the article it cites, and section 3 lists the searches that found the articles.
6 cost-effectiveness analyses and 2 studies reporting utility weights · 6 sources
Overview
| Item | Detail |
|---|---|
| Literature searched | Tufts Medical Center Cost-Effectiveness Analysis Registry, searched October 21, 2026; the queries are listed in section 3. |
| Cost-effectiveness analyses | 6 |
| Studies reporting utility weights | 2 |
Cost-effectiveness analyses
Analyses of Ulixacaltamide
No evidence found.
Treatments for the same indication
Magnetic resonance-guided focused ultrasound versus no surgery, radiofrequency thalamotomy, and deep brain stimulation in medication-refractory essential tremor, Canada: Li et al. (2019)
Relevance: Evaluates magnetic resonance-guided focused ultrasound thalamotomy against no surgery, radiofrequency thalamotomy, and deep brain stimulation in medication-refractory essential tremor from a Canadian public payer perspective, the analysis section 4.1 cites for the ablative and stimulation procedures listed in section 2.
Access: Not open access
Not quoted: The results for the comparisons with radiofrequency thalamotomy and deep brain stimulation are reported in the full text, which is closed access.
“We conducted a cost-utility analysis using a Markov cohort model.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We compared magnetic resonance-guided focused ultrasound with no surgery in people ineligible for invasive neurosurgery and with radiofrequency thalamotomy and deep brain stimulation in people eligible for invasive neurosurgery.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the reference case analysis, we used a 5-year time horizon and a public payer perspective and discounted costs and benefits at 1.5% per year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Compared with no surgery in people ineligible for invasive neurosurgery, magnetic resonance-guided focused ultrasound cost $21,438 more but yielded 0.47 additional quality-adjusted life years, producing an incremental cost-effectiveness ratio of $45,817 per quality-adjusted life year gained.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In people eligible for invasive neurosurgery, magnetic resonance-guided focused ultrasound was slightly less effective but much less expensive compared with the current standard of care, deep brain stimulation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Unilateral magnetic resonance-guided focused ultrasound versus unilateral deep brain stimulation and versus no procedure in medically refractory essential tremor, England: Jameel et al. (2022)
Relevance: Evaluates unilateral magnetic resonance-guided focused ultrasound against unilateral deep brain stimulation and against no procedure in medically refractory essential tremor from the perspective of NHS England, procedures listed as treatment options in section 2.
“A Markov cohort model was developed to estimate the cost-effectiveness of MRgFUS in England as a treatment for moderate to severe mrET in England.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cost-utility analysis performed from the perspective of NHS England.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“3.5% discount rate was applied to costs and utilities in the model in line with NICE guidelines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Model outcomes were the total costs per patient (2019 GBP) and quality-adjusted life-years (QALYs) for each strategy over a 5-year time horizon based on the available temporal data for MRgFUS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MRgFUS was less costly (£19,779 vs £62,348) and more effective generating 0.03 additional QALYs (3.71 vs 3.68) per patient over the 5-year time horizon (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thus MRgFUS is economically dominant compared to DBS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients not suitable for DBS, the MRgFUS strategy cost over £16,000 more than medication alone (£19,779 vs £3,735) but yielded 0.77 additional QALYs (3.71 vs 2.95) per patient, producing an ICER of £20,851 per QALY gained over a 5-year horizon.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When using a WTP threshold of £30,000, the MRgFUS strategy was more cost-effective than no procedure in 66% of the 1,000 iterations” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
The same disease in other populations or settings
No evidence found.
Related diseases and analogous treatments
MR-guided focused ultrasound thalamotomy added to medical therapy, and deep brain stimulation, in tremor-dominant Parkinson's disease, Canada: Meng et al. (2021)
Relevance: Evaluates magnetic resonance-guided focused ultrasound thalamotomy added to medical therapy, and deep brain stimulation, in tremor-dominant Parkinson's disease in Canada, a tremor disorder treated with the procedures section 2 lists for essential tremor.
“The authors used a decision tree model with rollback analysis and one-factor sensitivity analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Costs in Canadian dollars (CAD) were derived from the Schedule of Benefits and Fees in Ontario, Canada, and expert opinion on usage.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“MRgFUS was associated with an expected cost of $14,831 CAD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adding MRgFUS to continued medical therapy resulted in an incremental cost-effectiveness ratio of $30,078 per quality-adjusted life year (QALY), which remained cost-effective under various scenarios in the sensitivity analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Comparing DBS to MRgFUS, while DBS did not achieve the willingness-to-pay threshold ($56,503 per QALY) in the base case scenario, it did so under several scenarios in the sensitivity analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Deep brain stimulation with medical therapy versus best medical therapy alone in advanced Parkinson's disease, United States: Pietzsch et al. (2016)
Relevance: Evaluates deep brain stimulation with medical therapy against best medical therapy alone in advanced Parkinson's disease from a United States Medicare payer perspective, the procedure section 2 lists for essential tremor.
“We used a decision-analytic state-transition (Markov) model to project PD progression and associated costs for the two treatment strategies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We estimated the discounted incremental cost-effectiveness ratio (ICER) in U.S. dollars per quality-adjusted life-year (QALY) from the Medicare payer perspective, considering a ten-year horizon, and evaluated the robustness of our projections through extensive deterministic sensitivity analyses.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Over ten years, DBS treatment led to discounted total costs of $130,510 compared to $91,026 for BMT and added 1.69 QALYs more than BMT, resulting in an ICER of $23,404 per QALY.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This ICER was relatively insensitive to variations in input parameters, with neurostimulator replacement, costs for DBS implantation, and costs for treatment of disease-related falls having the greatest effects.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Across all investigated scenarios, including a five-year horizon, ICERs remained under $50,000 per QALY.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Deep brain stimulation versus status before treatment in dystonia, United Kingdom: Yianni et al. (2005)
Relevance: Evaluates deep brain stimulation against pretreatment status in dystonia in the United Kingdom, a related movement disorder treated with the procedure section 2 lists for refractory essential tremor.
“To perform a preliminary cost-utility and cost-benefit of deep brain stimulation (DBS) in the treatment of dystonia” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We conducted a prospective study of 26 patients undergoing DBS for the treatment of dystonia.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We performed a cost-utility analysis using the Euroquol (EQ-5D) questionnaire.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We found that the EQ-5D score improved from 29 to 76.2 points after surgery, an incremental utility of 0.47.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There was an overall gain of 0.94 quality-adjusted life-years (QALY) with a cost of £33,980 per QALY.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
AbobotulinumtoxinA versus best supportive care in cervical dystonia, United Kingdom: Muthukumar et al. (2017)
Relevance: Evaluates abobotulinumtoxinA against best supportive care in cervical dystonia over a lifetime horizon in the United Kingdom, the botulinum toxin treatment section 2 lists for refractory essential tremor applied in a related movement disorder.
“A Markov model was developed to evaluate the cost-effectiveness of abobotulinum-toxinA versus best supportive care (BSC) in CD, with a lifetime horizon and health states for response, nonresponse, secondary nonresponse, and BSC in patients with CD (mean age: 53 years; 37% male).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The analysis adopted the perspective of the UK NHS and PSS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Model costs and outcomes were discounted at 3.5% per annum based on the National Institute for Health and Care Excellence reference case.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The currency year for the analyses was 2013.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The total incremental QALYs gained from abobotulinumtoxinA compared to BSC was 0.235 per patient, with the total incremental cost being £7,160. This corresponds to an ICER of £30,468 per QALY gained.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Changing the time horizon to 5 years resulted in total incremental costs of £2,809, incremental QALYs of 0.083, and an ICER of £38,117.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The CEAC showed that abobotulinumtoxinA had a 46% probability of being cost-effective at a threshold of £20,000 compared to BSC without BoNT-A injections.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Utility weights
Utility weights from analyses of Ulixacaltamide
No evidence found.
Utility weights for the same indication
No evidence found.
Utility weights for the same disease in other populations or settings
Utility weights for disabling essential tremor, tremor improvement after surgery, recurrence, and procedural complications: Li et al. (2019)
Relevance: Utilities for disabling essential tremor, tremor improvement after surgery, tremor recurrence, and procedural complications, from a Canadian model of magnetic resonance-guided focused ultrasound.
Access: Not open access
Not quoted: The utility weights are reported in the full text, which is closed access.
Utility weights for disabling essential tremor and for tremor improvement after focused ultrasound or deep brain stimulation, with and without adverse events: Jameel et al. (2022)
Relevance: Utilities for disabling essential tremor at baseline and for marked or mild to moderate improvement after focused ultrasound or deep brain stimulation, with and without adverse events, in the short and long term.
“Values included the utility in each health state, and the disutility incurred from treatment-related adverse events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Utility weights for related diseases and analogous treatments
No evidence found.
Search strategy
| Dataset | Query | Results |
|---|---|---|
| Methods | ulixacaltamide OR "PRAX-944" OR "Z944" | 0 |
| Ratios | "essential tremor" OR "tremor" | 7 |
| Methods | "essential tremor" OR tremor | 4 |
| Ratios | "focused ultrasound" OR thalamotomy OR "radiosurgery" AND tremor | 0 |
| Methods | "focused ultrasound" | 14 |
| Ratios | propranolol OR primidone OR topiramate | 140 |
| Weights | "essential tremor" OR tremor | 45 |
| Ratios | "deep brain stimulation" | 64 |
| Ratios | ethosuximide OR "T-type calcium" | 0 |
| Ratios | "cervical dystonia" OR dystonia | 11 |
| Ratios | "peripheral nerve stimulation" OR "transcutaneous afferent patterned stimulation" | 0 |
| Methods | primidone | 0 |
| Ratios | thalamotomy OR "radiofrequency thalamotomy" OR "gamma knife" | 12 |